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Abstract
Targeting cancers with amplified or abnormally activated c-Met (hepatocyte growth factor receptor) may have therapeutic
benefit based on nonclinical and emerging clinical findings. However, the eventual emergence of drug resistant tumors
motivates the pre-emptive identification of potential mechanisms of clinical resistance. We rendered a MET amplified gastric
cancer cell line, GTL16, resistant to c-Met inhibition with prolonged exposure to a c-Met inhibitor, PF-04217903 (METi).
Characterization of surviving cells identified an amplified chromosomal rearrangement between 7q32 and 7q34 which
overexpresses a constitutively active SND1-BRAF fusion protein. In the resistant clones, hyperactivation of the downstream
MAPK pathway via SND1-BRAF conferred resistance to c-Met receptor tyrosine kinase inhibition. Combination treatment
with METi and a RAF inhibitor, PF-04880594 (RAFi) inhibited ERK activation and circumvented resistance to either single
agent. Alternatively, treatment with a MEK inhibitor, PD-0325901 (MEKi) alone effectively blocked ERK phosphorylation and
inhibited cell growth. Our results suggest that combination of a c-Met tyrosine kinase inhibitor with a BRAF or a MEK
inhibitor may be effective in treating resistant tumors that use activated BRAF to escape suppression of c-Met signaling.
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Introduction
Aberrant receptor tyrosine kinase (RTK) activity provides
growth and survival signals crucial for the development and
progression of many cancers. Treatment of patients with targeted
inhibitors of key oncogenic kinase drivers such as sunitinib,
erlotinib, gefitinib, and imatinib have demonstrated clinical
success [1]. However, despite successful clinical outcomes in select
patient populations, the development of resistance to targeted
inhibitors can result in disease progression and limit therapeutic
effectiveness. Notably, the emergence of secondary mutations or
upregulation of compensatory pathways in response to RTK
inhibition often arises after a period of initial efficacy [2,3,4,5].
The c-Met/HGFR receptor tyrosine kinase is a promising
therapeutic target as mutations of c-Met (in papillary renal cell
carcinoma, childhood hepatocellular carcinoma) and focal ampli-
fications of the MET gene locus (in NSCLC, GBM, esophageal
and gastric cancers) may indicate an oncogenic dependence on c-
Met signaling [6,7,8]. For instance, cell lines and xenograft tumors
bearing amplification of the MET gene locus are very responsive to
c-Met inhibitors such as the highly selective small molecule PF-
04217903 (METi). Not unlike the eventual resistance that emerges
against other RTK inhibitors, several studies have described
development of resistance to c-Met inhibitors via c-Met amplifi-
cation [9] or c-Met mutations that prevent the inhibitor from
binding [10]. Additionally, the activation of EGFR/ERBB family
receptors [2,11,12], KRAS, BRAF, or AKT [13] can also
overcome c-Met inhibition.
To anticipate potential resistance, we utilized an in vitro screen to
select for METi resistant clones of GTL16, a c-Met dependent
gastric carcinoma cell line that harbors a high-level focal
amplification of the MET gene locus [12,14]. Here we report a
novel escape mechanism of GTL16 treated with METi. Molecular
characterization of resistant clones reveals a genomic rearrange-
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from SND1 and BRAF. SND1 is a multi-functional ribonuclease
comprising part of the RNA-induced silencing (RISC) complex
[15,16,17]. It plays a role in the function of microRNAs (miRNA)
and can regulate transcription through transcriptional co-activa-
tion, RNA interference, RNA splicing, and RNA editing [18].
Increased expression of SND1 is associated with colon cancer and
prostate cancer [15]. Overexpression of SND1 also promotes
angiogenesis in hepatocellular carcinoma xenograft models
through induction of angiogenic factors [19].
BRAF is a proto-oncogene that promotes cell growth and
proliferation by transducing signals from growth factor receptors
as part of the MAP kinase pathway via MEK and ERK. Mutations
to this protein such as G469A, E586K, V600E, and K601E can
increase BRAF catalytic activity [20]. BRAF V600E has been
implicated in papillary thyroid carcinoma [21], colorectal carci-
noma [22], and melanoma [23]. Similarly, various fusions of
BRAF have been implicated in cancer such as pediatric
astrocytomas (KIAA1549-BRAF; exons 9/11) [24], melanocytic
nevi (FCHSD1-BRAF; exon 9) [25], papillary thyroid carcinomas
(AKAP9-BRAF; exon 9) [26], prostate cancer (SLC45A-BRAF;
exon 8) [27], and gastric cancer (AGTRAP-BRAF; exon 8) [27].
In our model, the resultant SND1-BRAF fusion protein
contains a constitutively active BRAF kinase which increases
phosphorylation of ERK. Functionally, this fusion protein signals
downstream of c-Met and bypasses its inhibition by METi. We
demonstrate that a MEK inhibitor or the combination of c-Met
and RAF inhibitors suppresses phosphorylation of ERK and
reduces the proliferation of the resistant clones in vitro. Together,
these findings suggest that targeted inhibitors can be bypassed at
multiple levels and that inhibiting the nodes where the signal
converges might be a more robust strategy for therapy.
Materials and Methods
Generation of Resistant Clones
GTL16 cells were seeded in a 96-well plate at a density of
20,000 cells per well and treated with 0.5 mM PF-0461903
(METi), a selective c-Met kinase inhibitor (Figure S1). The
concentration of METi was progressively increased once every two
weeks by 0.5 mM increments until a final concentration of 2.5 mM.
METi was replenished every 3–5 days as needed. After a total of
4 months, wells with surviving cells at 2.5 mM METi were
trypsinized, and subcloned using cloning rings. Three clonal lines,
designated GTL16R1, GTL16R3 and GTL16S5 were expanded
for further study. The GTL16 gastric cancer cells were a gift from
Dr. Paolo Comoglio from the University of Torino Medical
School, Candiolo, Italy.
Cell Viability Assays
Cell viability assays were performed using the GTL16 line and
GTL16 resistant clones. Briefly, cells were seeded at a density of
4000 cells/well into 96-well plates and allowed to adhere
overnight. The following day, cells were treated with either single
agent or combination of METi and a Raf inhibitor, PF-04880594
(RAFi) (Figure S2) or a MEK inhibitor, PD-0325901 (MEKi) [28]
as indicated in the figures. For single agent treatment, we
administered compound in nine serial concentrations (progres-
sively decreasing from 10 mM to 153 pM by a 4-fold ratio) yielding
a full sigmoidal curve. For combinations, we added a second
compound (RAFi or MEKi) in five serial concentrations ranging
from 10 mM to 39 nM by a 4-fold dilution ratio for RAFi, and
from 10 nM to 40 pM by a 4-fold dilution ratio for MEKi. After
an additional 3-day incubation at 37uC, 30 ml of Cell Titer Glo
(Promega, Madison, WI) was added to indirectly measure cell
viability/proliferation using an Envision multi-reader (Perkin-
Elmer, Waltham, MA). The BLISS independence algorithm was
used to calculate theoretical combination additivity [29]. The
DBLISS score was calculated as the difference between BLISS and
experimentally observed inhibition and ranges from 0 (additive) to
1 (synergistic). Graphical surface plots were rendered using the
Lattice R library [30].
Data Processing
Briefly, readings from the Envision multi-reader were processed
using the R package ’drc’ (drug response curves) to generate IC50
values [31]. Cell counts were first adjusted by subtracting the
average of the baseline cell counts from untreated cells assessed
one day after cell seeding. The Tumor Cell Growth Inhibition
(TGI) score for each compound concentration was calculated as:
TGI~1- well count-baseline ðÞ = plate control mean-baseline ðÞ ðÞ
.
The drc package was then used to fit the TGI as a function of
the concentration of the compounds. A four-parameter logistic
model was used to fit the dose response curves and infer the IC50,
slope, and upper and lower limits.
Analysis of Cell Signaling by Inhibitor Treatment
GTL16 and resistant clones were grown to approximately 80%
confluency and then treated with inhibitor compounds or DMSO
vehicle control at the indicated concentrations and time duration.
For Western immunoblotting, cells were rinsed with phosphate
buffered saline (PBS) and subsequently lysed with cell lysis buffer
(Cell Signaling, Danvers, MA) supplemented with 2 mM sodium
orthovanadate and 2 mM phenylmethylsulfonyl fluoride (PMSF).
Cell lysates were harvested, sonicated briefly, and incubated for
1h ra t4 uC. Lysates were then centrifuged at 14,000 rpm for
10 min at 4uC to pellet cell debris, and supernatant was collected.
Reverse Phase Protein Array (RPPA)
GTL16 and resistant clones were treated with 2.5 mM METi or
vehicle control for 1 hr and lysed with CLB lysis buffer according
to the vendor’s directions (Zeptosens, Basel, Switzerland). Lysates
were sent to Zeptosens for analysis. RPPA data from Zeptosens
was processed by the vendor and further processed by median
centering. Heatmap plots were generated using a custom R script
with scaling to a range of 23 to 3 (arbitrary value).
Western Immunoblots
The protein concentration of cell lysates was quantified using a
DC protein assay kit (Bio-Rad, Hercules, CA). Forty to seventy-six
mg of total protein per lane were loaded in a 4–12% gradient BIS-
TRIS SDS-PAGE gel (Invitrogen, Carlsbad, CA, NuPAGE) or
Criterion XT gel (Bio-Rad), and was transferred onto nitrocellu-
lose membrane (Bio-Rad, #162-0233 or Invitrogen, #IB3010-
01). Membranes were blocked with Phosphoblocker (Cell Biolabs,
San Diego, CA) and incubated overnight with primary antibody
diluted in Phosphoblocker. Primary antibodies were used accord-
ing to manufacturer’s recommendation: phospho BRAF S445
(Cell Signaling, #2695); BRAF N-term (Cell Signaling, #9433);
BRAF c-TERM C-19 (Santa Cruz Biotechnology, Santa Cruz,
CA); phospho c-Met Y1349 (Cell Signaling, #3121); c-Met (Cell
Signaling, #3127); phospho ERK T202/Y204 (Cell Signaling,
#9106); ERK (Cell Signaling, #9102); phospho AKT S473 (Cell
BRAF Fusion Confers Resistance to c-Met Inhibitor
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Signaling, #4968).
Microarrays
RNA and DNA were isolated using RNeasy and DNeasy kits
(Qiagen, Germantown, MD) for microarray analysis. Whole
genome expression profiling and copy number analysis were
performed using Affymetrix HGU133 Plus 2.0 and SNP 6.0 arrays
(Affymetrix, Santa Clara, CA), respectively, per manufacturer’s
protocol. HGU133 Plus 2.0 data were GC Robust Multiarray
Average normalized using R and the gcrma package from
bioconductor.org [32].
Affymetrix SNP 6.0 data were processed using the aroma.affy-
metrix R package according to the methods of H. Bengtsson et al.,
using the GTL16 as the reference baseline [33].
All array data is MIAME compliant and will be publically
available from the Gene Expression Omnibus (GEO) under
accession GSE27692.
59 Rapid Amplification of cDNA Ends (RACE)
RNA ligase-mediated, rapid amplification of cDNA ends was
performed on total RNA from GTL16, GTL16R1, and
GTL16R3 clones using a Generacer
TM kit (Invitrogen, Carlsbad,
CA). PCR primers specific for 59 generacer oligo sequence [59-
cgactggagcacgaggacactga -39] and 39 primer targeting BRAF exons
11 and 12 junction [59-catcaccatgccactttcccttgt-39] were used to
amplify a first-strand cDNA generated using random hexamers.
PCR was performed using 1X Titanium Taq PCR buffer, 0.2 mM
dNTP, 0.4 mM forward generacer and reverse BRAF primers, and
1X Titanium Taq DNA polymerase (Clontech Laboratories,
Mountain View, CA). The sequence of cycling was 1 cycle at 95uC
for 60 sec; 5 cycles at 95uC for 15 sec, 72uC for 90 sec; 5 cycles at
95uC for 15 sec, 70uC for 90 sec; 25 cycles at 95uC for 15 sec,
68uC for 90 sec, and an additional extension at 68uC for 7 min
using Peltier Thermal Cycler 200 (MJ Research, Waltham, MA).
The PCR product was run on a 1.2% agarose gel and a 2.1 Kb
amplicon was gel-purified, cloned into pCRH4-TOPOHR cloning
vector (Invitrogen, Carlsbad, CA), and sequenced using M13
forward and reverse primers on a 3730XL capillary sequencer
(Applied Biosystems, Foster City, CA). Sequence data was
analyzed using Sequencher (Gene Codes Corporation, Ann Arbor,
MI).
Kinase Selectivity Screens
The METi and RAFi were screened against kinase panels
(SelectScreen, Invitrogen; University of Dundee, Division of Signal
Transduction Therapy, UK; Upstate Biotechnology/Millipore,
Billerica, MA). In these selectivity assays the concentration of ATP
was set to the Km value of ATP for each kinase tested to allow for
a relative potency comparison between the various kinases. The
compounds were tested at 1 mM final concentration. Some of the
kinases that showed modest potency in the percent inhibition
biochemical assays were further evaluated in a dose response cell
based assay. For example METi showed biochemical inhibition of
IGF1R but did not inhibit IGF1R kinase activity in the follow-up
cell based assay.
Next Generation Sequencing
RNA-Seq libraries were generated and quality assessed as
previously described [34,35] and sequenced on Illumina GA2
instruments. Paired end reads (75 bases each) were aligned to
RefSeq transcripts using the BWA alignment tool [36] on default
settings and processed to BAM files with samtools [37]. BAM files
were deposited into the European Nucleotide Archive under
accession ERP001432. Aberrantly mapped pairs were identified
using the BAM_preprocessingPairsMisMatch.pl script from
SVDetect (r0.6d) [38]. Frequency of mismatched transcripts was
counted using a custom script. All read pairs for the potential
fusion transcript were extracted with samtools from the original
BAM file and de novo assembled into contigs using velvet (v1.0.13)
[39] and further constructed into transcripts using oases (v0.1.16)
(http://www.ebi.ac.uk/ ˜zerbino/oases/). Putative fusion tran-
scripts were then aligned by BLAST [40] to the original RefSeq
transcripts (SND1 NM_014390.2 and BRAF NM_004333.4) to
identify the composition of the transcript and the position of the
fusion junction. The sequence for the most complete transcript
was deposited in GenBank under accession JX013981. Coverage
data was generated using the pileup function from samtools.
Fusion Search in Public CNV Datasets
Computational search was performed using publically available
CNV (Copy Number Variation) arrays from:
TCGA (http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp).
Sanger (http://www.sanger.ac.uk/genetics/CGP/Archive/).
Broad (http://www.broadinstitute.org/tumorscape/pages/
portalHome.jsf).
GEO (http://www.ncbi.nlm.nih.gov/geo/) (GSE13429,
GSE14437, GSE14960, GSE14994, GSE15096, GSE15264,
GSE15526, GSE15688, GSE16619, GSE17247, GSE17958,
GSE18333, GSE18828, GSE19416, GSE19539, GSE20709,
GSE21780, GSE21990, GSE22208, GSE22306, GSE22615,
GSE23300, GSE23452, GSE25016, GSE25839, GSE27560,
GSE7822, GSE9829).
GSK (https://cabig.nci.nih.gov/caArray_GSKdata/).
Results
Generation and Characterization of METi Resistant GTL16
Clones
GTL16 cells were cultured in the presence of increasing
concentrations of METi up to 2.5 mM over a period of four
months. Following treatment, GTL16 cells that grew at a rate
similar to untreated GTL16 cells were defined to be resistant. The
resulting cells from distinct wells appeared as a homogenous
population that appeared either rounded (R) or squamous-like (S)
(Figure 1A). Resistant clones, GTL16R1 and GTL16R3 did not
respond to growth inhibition by METi at concentrations up to
10 mM, while GTL16 were sensitive with an IC50 of 10 nM
(Figure 1B). To determine if resistance was a compound specific or
a target specific phenomena, we also treated the GTL16R1 and
GTL16R3 clones with the c-Met/ALK inhibitor, crizotinib. We
observed an IC50 value .1 mM for the resistant clones, while
GTL16 had an IC50 of 3 nM (Figure 1C). Data for the rounded
clones (GTL16R1 and GTL16R3) are presented below. The
squamous clones are pending further characterization but are
resistant to c-Met inhibition by a different but unknown
mechanism that does not involve BRAF or the c-Met receptor
directly.
Molecular Profiling to Understand Resistance
Mechanisms
To examine the effect of METi on the activation state of signal
transduction pathways, protein lysates from GTL16 and the
resistant clones were assayed with Reverse Phase Protein Arrays
(RPPA) for select total and phosphorylated proteins. Treatment of
GTL16, GTL16R1, and GTL16R3 with 2.5 mM METi for 1 hr
inhibited phosphorylation of c-Met residue Y1235 (Figure 2).
BRAF Fusion Confers Resistance to c-Met Inhibitor
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treated samples compared to vehicle-treated samples, showing that
the decrease in phosphorylation was not simply due to a reduction
in the amount of total protein (Figure 2). Inhibition of the Y1235
autophosphorylation site, which is critical for c-Met receptor
kinase activation [41], indicates that the mechanism of resistance
in clones GTL16R1 and GTL16R3 is not due to an inability of
METi to bind c-Met kinase and inhibit its catalytic activity.
Furthermore, a compensatory increase in c-Met expression in the
GTL16R1 and GTL16R3 clones is insufficient to sequester the
compound and restore signaling. Interestingly, tyrosine phosphor-
ylation of EGFR, ERBB2, ERBB3, ERBB4, and SRC was also
inhibited upon METi treatment. One explanation for this decrease
is that overexpressed c-Met transactivates these proteins (Figure 2).
The relative fold change of phosphorylation by METi treatment is
summarized in Figure S3.
To further assess the mechanism of resistance to c-Met
inhibition, METi-resistant clones were profiled for gene expression
with Affymetrix U133 Plus 2.0 chips and for DNA Copy Number
Variation (CNV) using Affymetrix SNP 6.0 arrays. GTL16R1 and
GTL16R3 clones have a nearly identical CNV profile to GTL16
except for a 4-fold amplification of ,356 KB in 7q31 and ,2
megabases within 7q34. Relative to GTL16, most genes within
7q34 had a corresponding increase in mRNA expression with
BRAF expressed more than 32-fold in both GTL16R1 and
GTL16R3 (Figure 3).
BRAF Fusion Identification
Affymetrix SNP 6.0 array analysis indicated a segmentation
breakpoint that bisected the genomic BRAF gene structure within
intron 8 (Figure 3). BRAF fusions have been reported previously,
and these commonly occur at exon 9 with an intact BRAF
Figure 1. The GTL16 gastric carcinoma cell line becomes resistant to c-Met inhibition after 4 months of continuous treatment with
METi. (A) METi-resistant cells exhibit distinct squamous-like and rounded morphologies compared to GTL16 cells. 100X magnification. (B) Cell
viability response curves to METi. METi inhibits GTL16 (blue) with an IC50 value of 10 nM, while it does not inhibit cell viability in clones GTL16R1 and
GTL16R3 (red and green). Inhibition of cell viability is normalized relative to untreated control cells. (C) Cell viability response curves to crizotinib.
Crizotinib inhibits GTL16 (blue) with an IC50 value of 3 nM. While IC50 values for GTL16R1 and GTL16R3 are .1 mM.
doi:10.1371/journal.pone.0039653.g001
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GTL16R3, and the squamous-like (GTL16S5) resistant clone
lysates by Western immunoblot with N-terminal-, C-terminal-,
and phospho-specific BRAF antibodies. All three BRAF antibodies
identified wild-type BRAF in all samples (Figure 4A, arrows). By
contrast, the C-terminal and phospho-specific BRAF antibodies
identified a higher molecular weight species in clones GTL16R1
and GTL16R3 that was absent in GTL16 and GTL16S5
(Figure 4A, arrowheads). The N-terminal-specific BRAF antibody
was not able to recognize the higher molecular weight species,
suggesting that both the GTL16R1 and GTL16R3 clones express
a species of BRAF lacking the N-terminal domain. Interestingly,
the higher molecular weight BRAF variant appears to be highly
phosphorylated at S445 compared to wildtype BRAF. Based on
these observations, we suspected a putative BRAF fusion protein
and sought to identify the N-terminal fusion partner. Using 59
RACE of GTL16R1 and GTL16R3 transcripts with a 39 primer
specific for BRAF exons 11 and 12 produced a 2.1 kb product.
Sequencing of the amplicon revealed SND1 (staphylococcal
nuclease and tudor domain containing 1) to be the fusion partner
(Figure 4B). SND1 is normally located on chromosome 7q31
approximately 12 Mb upstream of BRAF (7q34). Here, SND1
happens to be bisected by the small 7q31 amplification observed in
the GTL16R1 and GTL16R3 clones. The translocation yields a
SND1-BRAF fusion transcript with exon 16 of SND1 fused in-frame
to exon 9 of BRAF, resulting in a fusion transcript coding for
SND1 amino acids 1-593 coupled to BRAF amino acids 381–766
(Figure 4B and C). Global copy number analysis confirms that the
exons adjacent to the amplification breakpoints of SND1 and
BRAF are consistent with this junction (Figure S4).
Confirmation of SND1-BRAF Fusion Sequence
Using Illumina sequencing with GTL16, GTL16R1, and
GTL16R3 transcripts, we confirmed that the fusion junction was
identical to the sequence obtained by 59 RACE, and no other
nucleotide changes were observed for SND1 or BRAF. De novo
assembly of read pairs mapping to either SND1 or BRAF
produced a fusion transcript that consisted of nucleotides 1-2006
of RefSeq transcript NM_014390.2 (SND1) and 1202–2947 from
RefSeq transcript NM_004333.4 (BRAF). Wild type BRAF
transcripts were observed in the GTL16R1 and GTL16R3 clones
as evidenced by paired reads spanning between exons 8 and 9
(data not shown). GTL16 did not contain any paired reads where
one end mapped to SND1 and the other mapped to BRAF. In
contrast, GTL16R1 contained 628 chimeric pairs and GTL16R3
contained 702 chimeric pairs (Figure S4).
Consistent with a fusion transcript of SND1 and BRAF, we
observed uneven coverage distribution of the N-terminal region of
SND1 and the C-terminal region of BRAF. We computed
normalized reads per base per million reads (RBM) to compare
transcript coverage between samples. Relative to GTL16, the
RBM of bases 1-2006 of SND1 in GTL16R1 and GTL16R3 is
Figure 2. METi inhibits c-Met phosphorylation in both GTL16 and resistant GTL16R1 and GTL16R3 clones. Heatmap of Reverse Phase
Protein Array (RPPA) showing GTL16 and resistant clones GTL16R1 and GTL16R3 relative level of total and phosphorylated proteins. Red indicates
higher intensity vs green which indicates lower intensity. Cells were treated with DMSO vehicle or METi (2.5 mM) for 1 hr.
doi:10.1371/journal.pone.0039653.g002
BRAF Fusion Confers Resistance to c-Met Inhibitor
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39653approximately 2-fold higher, while bases 2007–3522 are equiva-
lent (Figure S5). Similarly for BRAF, bases 1-1201 have about the
same RBM in GTL16, GTL16R1 and GTL16R3, while bases
1202–2947 have about 20-fold more RBM in GTL16R1 and
GTL16R3 compared to GTL16. There is a steep change in
coverage at the fusion junction point at position 2006 for SND1
and 1202 for BRAF. (Figure S5).
Determination of the Functional Relevance of the Fusion
Event Utilizing a RAF Inhibitor
To test the functional significance of the BRAF fusion, we
treated with METi, RAFi, or a combination of both in cell viability
assays. Single agent treatment with RAFi did not alter growth of
GTL16, GTL16R1 or GTL16R3 (Figure 5A and B, x-axis).
However, GTL16R1 and GTL16R3 treated with METi in
combination with RAFi demonstrated an effective tumor cell
growth inhibition (TGI). To assess whether this combination was
additive or synergistic, we calculated the DBLISS score (see
methods). As shown in figure 5B, GTL16R1 and GTL16R3 both
have a maximal DBLISS score of 1 indicating a synergistic effect.
Maximal synergy occurs between .39 nM METi and .625 nM
RAFi for GTL16R1 while GTL16R3 achieves max synergy
.39 nM METi and .2.5 mM RAFi. Treating GTL16 with this
same combination of METi and RAFi did not demonstrate
additional growth inhibition compared with METi alone, consis-
tent with oncogenic addiction to c-Met signaling.
Figure 3. Copy Number Variation (CNV) indicates that BRAF is amplified and bisected in resistant clones. Relative to GTL16, CNV
analysis identifies a region of increased copy number at 7q34, with a breakpoint within the BRAF locus in GTL16R1 and GTL16R3. In conjunction with
Affymetrix expression analysis, genes within the amplified regions are coordinately over-expressed (indicated in red) normalized to GTL16. Expression
of the BRAF transcript is increased over GTL16.
doi:10.1371/journal.pone.0039653.g003
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MAPK Signaling
To further confirm that the BRAF fusion protein is indeed
signaling through the MAPK pathway, we treated GTL16R1 and
GTL16R3 with MEKi as a single agent or in combination with
METi. Surprisingly, unlike RAFi, single agent MEKi was very
potent and was able to inhibit tumor cell growth with an IC50
value of 1.5 and 4.5 nM for GTL16R1 and GTL16R3,
respectively (Fig 5A). GTL16 cells were also inhibited by single
agent MEKi with an IC50 value of 8.2 nM (Figure 5C, x-axis).
To determine if MEKi can synergize with METi, we tested with
a sub-optimal dose of MEKi (ranging from 10 nM to 156 pM).
Combination with 2.5 nM of MEKi yielded the best synergy as
demonstrated by the DBLISS plot (Figure 5C).
A Combination of METi and RAFi Increased Inhibition of
ERK Phosphorylation in the Resistant Clones
To elucidate the mechanism of synergy, we examined
modulation of signal transduction pathways by Western immuno-
staining total cell lysates from GTL16, GTL16R1 and GTL16R3
Figure 4. Chromosomal rearrangement at 7q32 and 7q34 results in a highly expressed SND1-BRAF fusion protein. (A) Western
Immunoblot of total protein lysates identify a higher molecular weight band (arrowhead) recognized only by the anti-C-terminal BRAF antibody, and
present exclusively in GTL16R1 and GTL16R3, consistent with a fusion event within BRAF. Additionally, the putative fusion BRAF is highly expressed
and hyperphosphorylated compared to wild-type BRAF (arrow in BRAF panels). (B) 59 RACE identified the nucleotide sequence of fusion junction
spanning exon 16 of SND1 and exon 9 of BRAF. (C) Schematic representation of CNV amplification of the N-terminal portion of SND1 (mapping from
exon 1 to 16) and the C-terminal protein of BRAF (mapping from exon 9 to exon 18).
doi:10.1371/journal.pone.0039653.g004
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and in combination (Figure 6). Phosphorylation of the c-Met
Y1349 docking site was consistently inhibited in GTL16,
GTL16R1, and GTL16R3 by METi, but not by RAFi or MEKi
alone (Figure 6A). This inhibition was achieved despite moderately
increased levels of total c-Met protein upon METi treatment,
suggesting that METi blocks c-Met activity in GTL16R1 and
GTL16R3 with similar efficacy as GTL16 (Figure 6A).
In GTL16R1 and GTL16R3, SND1-BRAF was constitutively
phosphorylated on BRAF S445 and levels did not respond
significantly relative to total SND1-BRAF protein upon treatment
with any inhibitor (Figure 6A). The Serine 445 residue has been
reported to be constitutively phosphorylated in BRAF [43], and
would not be expected to be affected by inhibitors of BRAF activity.
The c-Met tyrosine receptor kinase activates two major signal
transduction cascades, the RAS-RAF-ERK MAP Kinase pathway
and the PI3K/AKT pathway. We examined AKT activity via
phosphorylation of S473 on AKT using Western immunoblot.
Compared to GTL16, untreated levels of AKT pS473 were
approximately two-fold and six-fold lower in GTL16R1 and
GTL16R3, respectively (Figure 6A and C). Treatment with METi
reduced AKT S473 phosphorylation to ,10% in all cell lines.
RAFi alone reduced AKT pS473 levels in GTL16, while it
increased pS473 levels slightly in GTL16R1 and GTL16R3. A
combination of METi and RAFi decreased AKT pS473 to levels
comparable to METi alone. In contrast, treatment with MEKi
induced an approximately three-fold increase of AKT pS473 in all
cell types.
We also investigated ERK phosphorylation levels in response to
compound treatments. The basal phosphorylated ERK levels in
GTL16R1 and GTL16R3 were approximately 3 fold higher than
GTL16. In response to METi, ERK phosphorylation was
completely inhibited in GTL16, however, ERK phosphorylation
only decreased slightly in GTL16R1 and GTL16R3 (Figure 6A
and B).
Treatment with RAFi increased ERK phosphorylation two fold
in GTL16 as RAF inhibitors can transactivate homo/heterodi-
mers of RAF isoforms to increase MEK signaling [44,45]. Despite
the increased level of ERK phosphorylation, we did not observe an
increase in cell proliferation. Although treatment of GTL16R1
and GTL16R3 with RAFi decreased ERK phosphorylation by
approximately three fold, the level of phosphorylated ERK
remained comparable to untreated GTL16 (Figure 6B). This
could explain why RAFi alone did not inhibit cell proliferation of
the resistant clones (Figure 5B) because the GTL16 cells are being
driven by hyperactivation of c-Met signaling which activates
MAPK through a RAF independent mechanism. Since METi
completely blocks ERK phosphorylation in GTL16 cells, there are
likely no activating Ras mutations or other activated downstream
mediators of MAPK signaling. Only the treatment of GTL16R1
and GTL16R3 with a combination of METi and RAFi further
inhibited ERK phosphorylation to 38% and 10.5% of untreated
GTL16 (Figure 6B).
Since GTL16R1 and GTL16R3 seemed to shift signaling
towards the MAPK pathway and away from the PI3K/AKT
pathway, we tested whether the resistance was solely dependent
Figure 5. The c-Met inhibitor synergizes with either RAFi or MEKi. (A) Cell Viability of resistant GTL16R1 and GTL16R3 clones treated with
RAFi or MEKi as single agents. Resistance of GTL16R1 and GTL16R3 clones to RAFi single agent treatment suggests that c-Met is involved in signaling
independent of Raf. MEKi treatment inhibits cell viability as a single agent with IC50 values of 1.5 nM and 4.5 nM for GTL16R1 and GTL16R3,
respectively. (B) METi and RAFi synergistically inhibit tumor growth of GTL16R1 and GTL16R3 resistant lines. Wildtype GTL16 (WT), resistant GTL16R1
and GTL16R3 clones were cultured with a combination of METi and RAFi at the indicated nM concentrations. Matrix grid represents various
concentration combinations. Single agent activity can be seen for METi and RAFi on the respective edges of the plot. Tumor cell growth inhibition
(TGI) or DBLISS independence is indicated on the Z-axis and shaded according to the value in the legend. TGI ranges from low (no effect on growth)
to high (complete suppression of growth). DBLISS ranges from low (complete independence/additivity) to high (synergy). (C) METi and MEKi can
synergize in GTL16R1 and GTL16R3. Wildtype GTL16 (WT), resistant GTL16R1 and GTL16R3 clones were cultured with a combination of METi and MEKi
at the indicated nM concentrations. Matrix grid represents various concentration combinations. Single agent activity can be seen for METi and MEKi
on the respective edges of the plot. Tumor cell growth inhibition (TGI) or DBLISS independence is indicated on the Z-axis and shaded according to
the value in the legend. TGI ranges from low (no effect on growth) to high (complete suppression of growth). DBLISS ranges from low (complete
independence/additivity) to high (synergy).
doi:10.1371/journal.pone.0039653.g005
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was able to completely inhibit ERK phosphorylation in all cells.
Consistent with BRAF activation, these data indicate that METi
inhibition is bypassed downstream of c-Met and upstream of
MEK.
Discussion
In some cancers, dysregulated c-Met signaling results in
oncogene addiction, a dependence on the pathway to maintain
cancer cell growth and survival [46]. The MET locus is amplified
or mutated in selected tumor types, and these patients are
predicted to be responsive to treatment with c-Met inhibitors
[8,47]. Unfortunately, acquired resistance is a significant concern
for single agent therapy based on precedence with agents like
imatinib in CML and erlotinib in lung adenocarcinoma [48].
Here we describe a GTL16 cell line model of METi resistance.
We identify an activated SND1-BRAF fusion protein which
confers resistance to METi. BRAF promotes cell growth and
proliferation by transducing signals from growth factor receptors
as part of the MAP kinase pathway via MEK and ERK. Our
findings are consistent with a model of resistance where the fusion
Figure 6. Higher ERK activity coincides with highly expressed SND1-BRAF fusion proteins in GTL16R1 and GTL16R3. (A) Western
immunoblot of GTL16, GTL16R1 and GTL16R3 treated with inhibitors as single agent or combinations for 4 hr. (B) Densitometry measurement of the
relative intensity of phospho ERK normalized to total ERK within each sample. (C) Densitometry measurement of the relative intensity of phospho
AKT S473 normalized to total AKT within each sample.
doi:10.1371/journal.pone.0039653.g006
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hyperactivating the MAPK pathway in a c-Met independent
manner. As summarized in figure 7, several signaling cascades are
activated by the c-Met receptor including PI3K, SRC, and Ras
signaling. By inhibiting tyrosine phosphorylation of critical c-Met
residues used to recruit adapter proteins GRB2 and GAB1, METi
inhibits the recruitment and activation of Ras and prevents
activation of the MAPK pathway by the c-Met receptor. The
SND1-BRAF fusion, however, circumvents METi by signaling
downstream of the c-Met receptor to MEK. The resistance can be
overcome by treating with MEKi, or a combination of METi and
RAFi to target the SND1-BRAF fusion protein.
Like previously described BRAF fusion proteins, the specific
role of the N-terminal partner seems limited. Despite containing
an intriguing array of tandem Staphylococcal nuclease homologue
domains which function to capture RNA targets, the SND1
portion of the fusion protein likely does not directly contribute to
c-Met resistance because use of RAFi was able to restore sensitivity
to METi. Rather, we think transcription of the gene fusion is
driven by the SND1 promoter and SND1 replaces the N-terminal
regulatory region of BRAF which normally regulates BRAF
catalytic activity [49].
Importantly, the simultaneous combination treatment with both
METi and RAFi is required to reduce the phosphorylation of
ERK in GTL16R1 and GTL16R3 more than 50% compared to
basal pERK levels in GTL16 (Figure 6B). The inability of RAFi to
completely inhibit ERK phosphorylation and reduce cell prolif-
eration as a single agent suggests that c-Met signaling activates
MEK independent of RAF catalytic activity. In this model, both
the c-Met and BRAF pathways would need to be blocked to
reduce ERK phosphorylation, enough to inhibit cell proliferation.
Additionally, as revealed by RPPA in figure 2, METi treatment
decreases SRC activity, and may suggest that SRC dependent
signaling is another pathway active in GTL16 cells. Bertolli et al.
demonstrates that adding SRC inhibitors enhances inhibition of
cell viability by c-Met inhibition [50].
The role of PI3K activation in our particular resistant model
seems minor. Lower basal pAKT S473 levels in GTL16R1 and
GTL16R3 suggest less dependence upon PI3K signaling. Addi-
tionally, while METi treatment suppresses pAKT S473, MEKi
treatment dramatically increases pAKT S473, and yet still inhibits
cell viability, suggesting that suppressing AKT phosphorylation is
not a requirement for blocking cell proliferation (Figure 5A and
C). Indeed, these results are consistent with experiments by
Hoeflich et.al. where increases in AKT p473 were seen in response
to MEKi in several cell lines. While increases in AKT/PI3K
activity are associated with anti-apoptosis and enhanced cell
survival, Hoeflich et.al. postulated that AKT/PI3K pathway
activation in response to MAPK pathway inhibition is delayed and
may be too late to maintain cell viability [51]. Hence, in our
model, signaling through MEK seems sufficient for rescue from c-
Met inhibition.
It is unclear if prolonged exposure of GTL16 cells to METi
resulted in de novo SND1-BRAF fusion translocations, or if resistant
clones arose from an enrichment of pre-existing cells with these
translocations. The GTL16R1 and GTL16R3 are not identical
clones despite possessing the same SND1-BRAF fusion protein
product. RNA-Seq and exome sequencing data show clone-
specific SNPs. Furthermore, the CNV segmentation pattern
appears to be distinct in the 7q32–7q34 region. However, because
the breakpoints are so similar, it is possible that GTL16R1 and
GTL16R3 are subvariants of a common precursor cell that was
present in the GTL16 tumor which has since diverged over time
creating a subpopulation of SND1-BRAF cells in culture.
Additionally, the SND1-BRAF fusion is highly amplified in
GTL16R1 and GTL16R3, but is not detected via Next
Figure 7. A model highlighting the resistance mechanism in GTL16 GTL16R1 and GTL16R3. Highly expressed SND1-BRAF fusion protein
signals through the MEK/ERK pathway and short-circuits c-Met inhibition.
doi:10.1371/journal.pone.0039653.g007
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out the possibility of a small pre-existing pool of SND1-BRAF
expressing clones in GTL16.
The clinical significance of the SND1-BRAF fusion is unknown.
A computational search of publically available CNV arrays
representing more than 5000 cell lines and primary samples did
not identify any co-occurring SND1-BRAF breakpoints consistent
with the known fusion. It is likely that selective pressure from
prolonged drug treatment is required to generate SND1-BRAF
fusions in primary tumors.
The acquisition of additional oncogenic drivers has important
implications for targeted therapy. The sequential treatment of
tumors with targeted agents may allow sequential resistance to
develop if inhibitors are applied individually. Conceivably,
resistance mechanisms to BRAF inhibition like IGF-1R [52],
COT [53], NRAS [54], or PDGFRbeta [54] could also provide
alternate survival pathways in the context of c-Met inhibition. For
example, EGFR signaling is one example of a resistance
mechanism common to both c-Met inhibition [2] and BRAF
inhibition [55]. Additionally, in a study of BRAF mutated
Papillary Thyroid Carcinoma (PTC), c-Met expression was 3-fold
higher in the BRAF aggressive PTC vs. the BRAF non-aggressive
PTC [56]. Furthermore, c-Met amplification is a primary
resistance mechanism to the BRAF inhibitor PLX4032 in patient
derived melanoma cell lines [57]. Hence, c-Met and BRAF co-
activation may increase tumor robustness and resistance to
targeted therapy due to activation of multiple growth and survival
pathways. Further studies are needed to understand the comple-
mentarity and essential elements of c-Met and BRAF inhibition.
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(Division of Signal Transduction Therapy). Values in % inhibition
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RAFi. (C) Cell based dose response kinase inhibition of indicated
kinases by RAFi.
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Figure S3 Phosphorylation fold decreases upon PF-04217903
treatment of GTL16, GTL16R1 and GTL16R3 cells compared to
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fusion regions of SND1 or BRAF. Fold is calculated relative to
GTL16. Fusion regions are overrepresented in GTL16R1 and
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